Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: Role of drug metabolism, apoptosis and DNA repair

Blood Cancer Journal

Volumn 2, Issue 3, 2012, Pages

  Ding, Y ^a   Sun, C L ^a   Li, L ^b   Li, M ^c   Francisco, L ^a   Sabado, M ^a,e   Hahn, B ^a,f   Gyorffy, J ^a,g   Noe, J ^a   Larson, G P ^d   Forman, S J ^b   Bhatia, R ^b   Bhatia, S ^a,h  

^a Population Sciences   (United States)

^b City of Hope   (United States)

^c Information Sciences   (United States)

^d City of Hope   (United States)

^e CLAREMONT GRADUATE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DNA; GLUTATHIONE TRANSFERASE M1; GYRASE INHIBITOR; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER THERAPY; CASE CONTROL STUDY; CONTROLLED STUDY; DNA METHYLATION; DNA MODIFICATION; DNA REPAIR; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; DRUG INDUCED CANCER; DRUG METABOLISM; FOLLOW UP; GENE DELETION; GENE EXPRESSION PROFILING; GENE INSERTION; GENE INTERACTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTOXICITY; GENOTYPE; HODGKIN DISEASE; HUMAN; LETTER; LEUKEMOGENESIS; NONHODGKIN LYMPHOMA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84864037631     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.4     Document Type: Letter

References (15)

1. Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588-1593. (Pubitemid 30120817)
2. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008; 22: 240-248. (Pubitemid 351250527)
3. Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Uike N et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000; 6: 4091-4095.
4. Woo MH, Shuster JJ, Chen C, Bash RO, Behm FG, Camitta B et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 2000; 14: 232-237. (Pubitemid 30095376)
5. Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004; 10: 2675-2680. (Pubitemid 38509141)
6. Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008; 112: 741-749.
7. Przychodzen BP, Jankowska AM, Smieszek SP, Mohan SR, Tiu RV, Jasek M et al. Investigations of genetic risk factors in MDS and AML using high-density 6.0 Affymetrix arrays. 2008; San Francisco, CA, USA, p 638.
8. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959. (Pubitemid 30397141)
9. Kosoy R, Nassir R, Tian C, White PA, Butler LM, Silva G et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat 2009; 30: 69-78.
10. Dudbridge E. UNPHASED User Guide. MRC Biostatistics Unit: Cambridge, 2006.
11. Li L, Li M, Sun C, Francisco L, Chakraborty S, Sabado M et al. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/ acute myeloid leukemia and identifies patients at risk. Cancer Cell 2011; 20: 591-605.
12. Ye Z, Song H. Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis. Eur J Cancer 2005; 41: 980-989. (Pubitemid 40602849)
13. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172. (Pubitemid 28453294)
14. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. Jama 2008; 299: 2423-2436. (Pubitemid 351749241)
15. Robien K, Ulrich CM. 5, 10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 2003; 157: 571-582. (Pubitemid 36368527)